Novel treatment strategies for upper-tract urothelial cancer

DATE & PLACE
28 & 29 October 2022 (arrival on 27 October)


VENUE

Sheraton Oman Hotel
40 Way, Muscat 112, Oman


REGISTRATION INFORMATION

Registration is obligatory for access to the expert meeting. Please register here.


LEARNING OBJECTIVES

After attending the meeting, participants should be able to:

  • Discuss measures to improve the diagnostic process for SMA at your clinic
  • Examine the evolving treatment landscape in SMA
  • Discuss practical considerations for the implementation of gene therapy
  • Develop individualized care plans for your patients with SMA, and explain how multidisciplinary management could be optimized
  • Outline measures for optimal integration of novel treatments and identify relevant criteria for patient selection


TARGET AUDIENCE

This meeting is intended for neurologists and neuromuscular disease specialists from the Middle East region who are responsible for the diagnosis and management of patients with SMA.


LANGUAGE

The official language of this educational meeting is English.


CONTACT

Should you have any questions about this educational meeting, please email Katrin.Zahlmann@ologyeducation.org.


SMA Expert Exchange: Novel treatments in clinical practice
is organized by Ology Medical Education, a global provider of independent medical education that develops CME initiatives for the international medical and scientific community.

Final programme to be announced prior to the meeting.


Thursday 27 October, 2022

Arrivals

18:30–21:30 Welcome dinner

 

Friday 28 October, 2022

09:00–09:20 Welcome lecture on current clinical practice in SMA
Asmaa Al-Tawari

Session 1: Improving the diagnostic process

09:20–09:50 Expert presentation and Q&A on the diagnosis of SMA
Mohammed Al-Muhaizea
09:50–10:30 Small group activities/workshop sessions on diagnostic challenges and screening programmes
Moderated by the steering committee
10:30–10:50 Refreshment break
10:50–11:50 Group presentations and moderated discussion

Session 2: Implementing novel treatments

11:50–12:50 Expert presentation and Q&A on the evolving treatment landscape for SMA
Laurent Servais
12:50–13:50 Lunch break
13:50–14:50 Patient case presentations: gene therapy in clinical practice
Mohammed Al-Muhaizea, Asmaa Al-Tawari, Tawfeg Ben-Omran
14:50–15:50 Small group activities/workshop sessions on the implementation of novel treatments
Moderated by the steering committee
15:50–16:10 Refreshment break
16:10–17:10 Group presentations and moderated discussion
17:10–18:10 Panel discussion about the implementation of novel treatments
Moderated by Mohammed Al-Muhaizea
Conclusions of the day
Tawfeg Ben-Omran
19:30-21:30 Dinner

 

Saturday 29 October, 2022

09:00-09:10 Overview of the programme for Day 2
Asmaa Al-Tawari

Session 3: Optimizing multidisciplinary care

09:10–09:50 Case-based expert presentation and Q&A on pulmonary care in SMA
Rania Abusamra Abdelkarim
09:50–10:30 Case-based expert presentation and Q&A on physiotherapy in SMA
Elena Mazzone
10:30–11:30 Small group activities/workshop sessions on multidisciplinary care in SMA
Moderated by the steering committee
11:30–11:50 Refreshment break
11:50–12:50 Group presentations and moderated discussion
12:50–13:00 Outlook on the future of SMA care
Tawfeg Ben-Omran
13:00–14:00 Optional lunch

Departures

STEERING COMMITTEE

Mohammed Al-Muhaizea, MD

King Faisal Hospital and Research Centre
Riyadh, Saudi Arabia

Tawfeg Ben-Omran, MD, FRCPC, FCCMG, FACMG
Sidra Medicine
Doha, Qatar
Weill Cornell Medical College,
Dohar, Qatar, and New York, NY, USA

 

FACULTY

Laurent Servais, MD, PhD
Elena Mazzone, PT
Rania Abusamra Abdelkarim, MBChB, FRCPCH, HERMES, CCT(UK)

 

Disclosures of conflicts of interest

Mohammed Al-Muhaizea, MD

Receipt of grants/research supports: Novartis Gene Therapies, PTC Therapeutics, Roche
Receipt of honoraria or consultation fees: Biogen Inc., Novartis Gene Therapies, PTC Therapeutics, Roche
Participation in a company sponsored speaker’s bureau: Biogen Inc., Novartis Gene Therapies, Roche

Tawfeg Ben-Omran, MD, FRCPC, FCCMG, FACMG
Nothing to disclose.

 

FACULTY

Rania Abusamra Abdelkarim, MD, MBChB, FRCPCH, HERMES, CCT

TBC

Elena Mazzone, PT
Receipt of honoraria or consultation fees: Biogen Inc., Novartis Gene Therapies, Roche, Scholar Rock

Laurent Servais, MD, PhD
Receipt of grants/research supports: Biogen Inc., Novartis Gene Therapies, Roche
Receipt of honoraria or consultation fees: BioHaven, Biogen Inc., Novartis Gene Therapies, Roche, Scholar Rock
Participation in a company sponsored speaker’s bureau: Biogen Inc., Novartis Gene Therapies, Roche

PLANNERS AND MANAGERS
Ology Medical Education planners and managers have nothing to disclose.

An application for accreditation has been submitted to UEMS-EACCME® for 10.0 ECMEC® credits.

DISCLAIMER
This event was organized to promote the exchange and dissemination of scientific and medical information only, with no promotional activity permitted. The views expressed during each presentation are those of the speaker only, and do not necessarily reflect the views of the organizers or sponsors. The presentations may discuss therapeutic products that have not been approved, or off-label use of certain products. All content is provided for general educational purposes only and should not in any way be considered as advisory. It is the responsibility of the healthcare professional to verify all information and data before treating patients or using any therapies described. All presentations are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) any part of the material presented, you must obtain all the necessary permissions from the publisher, original author, and any other current copyright owner.

This programme has been made possible thanks to an unrestricted independent educational grant received from Novartis Gene Therapies (formerly AveXis).

Please register here for the SMA Expert Exchange: Novel treatments in clinical practice meeting.

There is no registration fee for this meeting. Travel (economy round-trip flights and transfer to meeting venue from the airport) and accommodation for two nights will be organized for all participants by Ology Medical Education.

Any alternative travel arrangements and incidental costs made by the participants will not be reimbursed. Following your registration, you will be contacted by the organizers for further details so that we can arrange your travel.

EDUCATIONAL PARTNER
Ology Medical Education
info@ologyeducation.org

SMA Expert Exchange: Novel treatments in clinical practice
28 & 29 October 2022 in Muscat, Oman
UEMS accredited expert meeting
This activity is supported by an independent educational grant from Novartis Gene Therapies.

Register

Welcome to SMA Expert Exchange: Novel treatments in clinical practice, an international expert meeting on spinal muscular atrophy (SMA) management.
During this event you will take part in a 1.5-day programme, comprising engaging activities including discussions of patient cases and workshop sessions addressing local challenges.
The meeting will also feature expert lectures and panel discussions, with opportunities for you to share experiences with your peers and receive feedback on clinical issues from leading global experts.
SMA Expert Exchange will help ensure that you are up to date with the latest data and thinking, offering practical guidance on early diagnosis, the implementation of novel treatment options, and how to optimize multidisciplinary care to meet local needs.

 

Related activities